Bupropion hydrochloride extended-release tablets are widely prescribed for the treatment of major depressive disorder and for ...

Interim phase 3 results showed the IL-13 monoclonal antibody improves histology and symptoms in EoE, even in participants ...

The medication is widely prescribed for the treatment of major depressive disorder and for the prevention of seasonal ...

Granules India's US subsidiary receives FDA approval for generic Bupropion Hydrochloride Extended-Release Tablets, expanding ...

Watsons, the leading health, wellness, and beauty retailer in the Philippines, recently held an engaging vaccination ...

Granules Pharmaceuticals, Inc., a 100% foreign subsidiary of Granules India received the U.S. Food & Drug Administration (USFDA) approval for abbreviated new drug application (ANDA) of Bupropion ...

Granules India announced today that the U.S. Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP (SR) ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and (BMC) have announced a new collaboration with the global biopharma company GSK to advance innovative research ...

GSK plc GSK announced that the FDA has accepted its new drug application (NDA) seeking approval for its investigational, ...

Shares of Wave Life Sciences WVE surged 74.1% on Wednesday after the company reported positive proof-of-mechanism data from ...